Heparin Dosing is Weight-Based, Not Age-Based
Heparin dosing is primarily based on body weight, not age alone, though age is an important modifier that affects both dosing requirements and bleeding risk.
Primary Dosing Strategy: Weight-Based Approach
The standard approach uses weight-based dosing with subsequent monitoring and adjustment 1:
For Venous Thromboembolism (VTE):
- Initial bolus: 80 units/kg IV
- Continuous infusion: 18 units/kg/hour
- Alternative: 5,000 unit bolus followed by at least 32,000 units/day infusion 1
For Acute Coronary Syndromes:
- Unstable angina/NSTEMI: 60-70 units/kg bolus (max 5,000 units) + 12-15 units/kg/hour infusion (max 1,000 units/hour) 1
- STEMI with fibrinolytics: ~60 units/kg bolus (max 4,000 units) + 12 units/kg/hour (max 1,000 units/hour) 1
Age as a Critical Modifier
While dosing calculations use weight, age significantly impacts heparin pharmacokinetics and bleeding risk:
Geriatric Considerations (>60 years):
- Higher plasma heparin levels and longer aPTTs occur at similar doses compared to younger patients 2
- Increased bleeding risk, particularly in women over 60 years 1, 2
- Lower doses may be required in elderly patients 2
- Age >60 years is an independent predictor of anticoagulant-associated bleeding 1
Pediatric Considerations:
- Infants and preschool children (<5 years) are less sensitive to heparin and require higher weight-based doses 3
- Age-dependent differences exist in both heparin concentration and anticoagulant effect 4
Monitoring and Adjustment Algorithm
- Calculate initial dose using actual body weight (no dose capping recommended) 5
- Measure aPTT or anti-Xa levels:
- Adjust doses based on monitoring, not age alone 1
- Consider age-related factors:
- Elderly: anticipate need for lower maintenance doses
- Young children: anticipate need for higher initial doses
Critical Caveats
- Obesity: Lower weight-adjusted doses may be needed in obese patients to achieve target anticoagulation 7
- Individual variability: Heparin response varies significantly between patients due to differences in protein binding, clearance, and distribution 1
- Preservative concerns: Use preservative-free formulations in neonates and infants to avoid benzyl alcohol toxicity 2
- Bleeding risk increases with: age >60 years, female sex, supratherapeutic clotting times, recent surgery/trauma, comorbidities, and concomitant antiplatelet agents 1
The evidence clearly demonstrates that while weight-based dosing is the foundation, age must be factored into both initial dose selection and ongoing monitoring intensity, with particular caution in elderly patients and higher doses anticipated in young children.